Samsung Biologics, a leading contract development and manufacturing organization, announced today the launch of Samsung Organoids, marking the company's strategic expansion into preclinical research services. The new offering provides advanced drug screening capabilities to support clients throughout the drug discovery and development process.
Samsung Organoids utilizes three-dimensional cell culture systems engineered to closely mimic human organs, delivering clinically relevant insights for understanding specific drug responses and improving lead selection. These organoid models are gaining prominence in pharmaceutical research due to their high similarity to live tissues and their applications in biomarker discovery and drug efficacy prediction.
The service supports precision screening to predict patient responses, streamline preclinical development, and accelerate timelines toward investigational new drug filings through comprehensive data-driven analysis of candidate molecules. This expansion positions Samsung Biologics to offer services spanning the entire drug development lifecycle, from target discovery and lead selection through preclinical development and clinical trial planning.
By leveraging its established expertise in development and manufacturing, Samsung Biologics will provide multi-modal insights into the characteristics and mechanisms of candidate molecules. The company aims to help clients address challenges that typically arise during the drug discovery phase, ultimately enhancing clinical success rates.
"The latest service launch reflects our unwavering commitment to driving innovation by improving drug success rates and creating new possibilities in personalized medicine," said John Rim, CEO and President of Samsung Biologics. "The addition of research services is a significant move for us to create added value for clients by supporting the drug life cycle from start to finish with thorough therapeutic analysis."
The launch of Samsung Organoids represents a strategic evolution for Samsung Biologics, which operates a global network with facilities in Korea, the United States, and Japan, and maintains a combined biomanufacturing capacity of 784 kL across five plants. The company has built its reputation on delivering end-to-end integrated services from late discovery to commercial manufacturing, specializing in diverse modalities including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.
With this expansion into preclinical research services, Samsung Biologics strengthens its position as a comprehensive partner for pharmaceutical and biotechnology companies seeking to accelerate drug development timelines while maintaining high quality standards. The integration of organoid technology into its service portfolio demonstrates the company's commitment to innovation and its focus on addressing evolving client needs in the competitive pharmaceutical development landscape.
Click here for the original news story.